Clinical Development Failure Risk: The inherent high failure rate of drug candidates in pre-clinical and clinical development stages could lead to significant financial losses and reputational damage for Evotec's partners and, by extension, Evotec's milestone and royalty revenues.

Partnership Dependency Risk: Evotec's business model relies heavily on collaborations and partnerships with pharmaceutical and biotech companies, meaning a significant portion of its revenue is dependent on the success and strategic decisions of its partners, which could change or terminate agreements.

Intellectual Property Protection Risk: The company's success depends on its ability to protect its proprietary technology and intellectual property, and failure to do so, or challenges from third parties regarding patent validity or infringement, could severely impact its competitive advantage.